Introduction
Peyronie's disease (PD) is an acquired idiopathic localized fibrosis of the penis involving the tunica albuginea of the corpus cavernosum resulting in penile curvature and sexual dysfunction. 1 PD is a common penile disorder affecting 3-9% of men. 2 Clinically, PD presents as any combination of penile pain, penile curvature and ED, and depresses the patient and partner both physically and psychologically. 3 Many cases resolve with no treatment; but if left untreated PD can cause fibrotic, nonexpansible thickening of relatively distinct areas of the corpora tunica, known as plaque formation. Clinical manifestations of penile plaque are penile deformity, penile pain and varying degrees of ED. 4, 5 PD has three distinct different phases, namely, acute, early chronic and chronic. 6 Oral medical treatments are indicated in acute and early chronic phases. The exact pathogenic mechanism of this disease has yet to be identified. However, in recent years, increased expression of transforming growth factor (TGF)-b1 in fibrotic plaques of patients with PD has been described. 7 Furthermore, an increase in oxidative stress has been postulated as potentially damaging for the tunica albuginea in acute phase of the disease. 8 Coenzyme Q 10 (2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone, CoQ 10 ) is a fat-soluble, vitamin-like quinone commonly known as ubiquinone or ubidecarenone. Ubiquinone is reduced to ubiquinole (CoQ 10 H 2 ) via semiubiquinone radical (CoQ 10 H). 9 The fully reduced form of CoQ 10 (CoQ 10 H 2 ) exerts strong effects against the oxidative damage of polyunsaturated fatty acids. 10, 11 It is to be noted that CoQ 10 is known to be the only endogenously synthesized lipid-soluble antioxidant. 9 Decreased CoQ 10 levels in serum, 12 as well as a decrease of the CoQ 10 H 2 /CoQ 10 ratio, 13 have been demonstrated in diseases associated with oxidative stress. PD is characterized by an initial inflammatory reaction (acute phase) followed by fibrous inelastic scar formation (chronic phase).
14 Inflammation produces oxygen-free radicals and it could be speculated that as inflammation in an acute or early chronic phase persists, an inability to respond to this with antioxidants may result in disease progression. CoQ 10 is one of the most potent antioxidants, which is used to regenerate other antioxidants (tocopheryl and ascorbate), and may serve important roles in protection against oxidative stress and free radical oxygen damage. 15 TGF-b1 is a key fibrogenic mediator. It has been reported that solubilized CoQ 10 suppresses the expression of TGF-b1 induced by dimethylnitrosamine in mouse liver and mouse embryonic fibroblast cells. 16 In addition, CoQ 10 activates NF-E2-related factor-2 (Nrf2). 16 Nrf2 overexpression itself reduces the basal expression of a-smooth muscle actin and TGF-b1. 16 Therefore, CoQ 10 -induced Nrf2 activation may suppress TGF-b1 expression. This study is the first prospective, double-blind, placebo-controlled randomized study on the effects of CoQ 10 supplementation in men with early chronic PD.
Materials and methods

Study participants
A prospective, double-blind, placebo-controlled randomized clinical trial was performed from June 2006 to May 2009 on 214 consecutive male patients aged 35-60 years affected by early chronic PD. They were selected from a tertiary specialized sexual dysfunction clinic. Early chronic PD was defined as pain during erection, penile curvature not affecting vaginal penetration, palpable hyperechoic plaque(s) without pain and calcifications, with a total area of o2 cm 2 , which was limited to the albuginea. 6 All the included patients had at least two previous failed medical treatments for their PD and reported ED with painful penile curvature of at least 12-month duration. ED was defined as the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. 17 Previous treatments for PD included oral therapy with propionyl-L-carnitine (25, 13.6%), potassium aminobenzoate (161, 87.5%), colchicine (69, 37.5%), tamoxifen (72, 39.1%) and various vitamins, including vitamin E and B 6 (155, 84.2%). All patients gave informed consents and the investigation was conducted in accordance with the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines and the principles of the Declaration of Helsinki. Inclusion criteria were disease duration 412 months,  patient age between 18 and 60 years, presence of ED  without any obvious organic causes other than PD,  presence of penile plaque demonstrated by basal and  dynamic ultrasonography and by palpation with a  maximum size of 2 cm   2 , previous failed medical therapies for PD, stable sexual relationship, presence of painful erections and penis recurvatum. Exclusion criteria included presence of other sexual dysfunction, the absence of a penile curvature, previous penile surgery or pelvic trauma, endocrinopathy, significant renal impairment (serum creatinine 41.8 mg per 100 ml), alcohol or tobacco use, supplementation with vitamins or traditional herbs in the previous 3 months, and therapies interfering with CoQ 10 such as antioxidants.
Inclusion/exclusion criteria
Evaluations
Baseline evaluation included a detailed medical and sexual history, physical examination, dynamic penile duplex ultrasonography (DPDU) before and after an intracavernous injection with 20 mg of prostaglandin E 1 , with measurement, in the state of full erection, of angle and direction of curvature (by means of two rigid rulers), and manual examination of plaque for detection of its volume, location and consistency. Data regarding disease duration, presence and severity of painful erections, erectile function (EF), penile plaque size and penile curvature degree were obtained at baseline evaluation. Laboratory analysis included measurement of serum luteinizing hormone, follicle stimulating hormone, total testosterone and prolactin. Additional safety evaluations, including measurement of serum aspartate aminotransferase, alanine aminotransferase, lactic dehydrogenase, creatine kinase, alkaline phosphatase and glucose, were also performed at baseline and at each follow-up point. EF was evaluated with the International Index of Erectile Function (IIEF-5), 18 and Sexual Encounter Profile (SEP) diary questions 2 ('Were you able to insert your penis into your partner's vagina?') and 3 ('Did your erection last long enough for you to have successful intercourse?'). EF was categorized as follows using the IIEF-5 total scores: no ED (22) (23) (24) (25) , mild ED (17-21), mild to moderate ED (12) (13) (14) (15) (16) , moderate ED (8-11) and severe ED (5-7). 19, 20 Presence and severity of painful erections was determined on a conventional 10-point visual analog pain scale (VAS) score ranging from 0 to 10, with 0 being no pain and 10 being severe pain. Plaque size and status (fibrous or calcified) assessment was conducted by ultrasound and plain X-rays. Plaque size was determined as the product of length and width in square centimeters. For a subjective judgment of penile curvature, patients were asked to sketch the erected penis. During [21] [22] [23] The radiologist was unaware of the patient allocation. The radiologist performing DPDU did not know the treatment allocation of subjects. To evaluate varying degrees of curvature and plaque size, a modified form of the Kelami classification system was used. 24 Patients were categorized into three groups: class I, plaque length p1 cm and curvature of p301; class II, plaque between 1 and 2 cm and 30-601 curvature; and class III, plaque 42 cm and curvature 4601. Patients who cannot be categorized into any of the classes (for example, patients with penile curvature 4601 and plaque length o2 cm) were classified to be in a higher category. 21, 25 Before randomized procedure, all the eligible patients received single-blind placebo capsules for 1 week (week À1). Those who reported a decrease of X20% in pain VAS score (placebo responders) were excluded. Of 214 recruited subjects, 186 met inclusion and exclusion criteria and consented to proceed with the study protocol.
Treatment protocol
Eligible patients were randomly assigned to doubleblind, fixed-dose treatment with either CoQ 10 or placebo. The randomization codes were centrally assigned by the coordination center after checking the main eligibility criteria. At baseline (week 0), the patients were randomly assigned to take 300 mg of CoQ 10 (Kaneka, Osaka, Japan) orally daily (group 1, n ¼ 93), or a similar regimen of placebo (group 2, n ¼ 93) during the 24-week treatment period. The placebo was a starch compound with the same color and size of CoQ 10 . The following procedures were adopted to ensure blindness. Independent pharmacists prepared, anonymized and certified starch tablets; and filled and sealed anonymous colorcoded boxes containing drugs or placebos. The randomization codes were opened only after all subjects had completed the study. Compliance was assessed by comparing the number of pills ingested with the number of days between dispensing visits.
Outcome measures
For the analysis of efficacy and safety, all patients were evaluated in each visit (every 4 weeks) by the investigator. There were two primary subjective outcome measures including plaque size and degree of curvature, and two primary objective outcome measures including a decrease in pain during erections and improvement of EF. The four designated secondary end points were: (i) the mean number of sexual attempts per week; (ii) responses to a Global Assessment Question (GAQ), 'Has the treatment you have been taking during this study improved your erections?'; (iii) treatment satisfaction as assessed using patient versions of the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire; 26 and (iv) improvement in penile artery indices. Follow-up points were weeks 4, 8, 12, 16, 20, 24 , and 4 weeks after stopping treatment. The following variables were assessed at each follow-up visit: EF by IIEF-5 and SEP diary questions 2 and 3; plaque characteristics by ultrasound and X-ray; subjective changes in penile curvature by sketch and pain during erection by VAS; mean sexual intercourse per week, responses to GAQ and treatment satisfaction by EDITS. DPDU was repeated at the end of trial (1 month after stopping medication) to assess objective changes in penile curvature and penile artery spectral traces. For the purposes of this trial, a X10% change in plaque size, a X51 change in penile curvature, a X20% change in pain during erection, and/or any changes in EDV, RI and PSV, and/or any change in IIEF-5 score and SEP diary questions 2 and 3 were considered an alteration (improvement or worsening). 27 Safety and tolerability assessments Safety and tolerability were evaluated on the basis of spontaneously reported adverse events (AEs), clinical laboratory tests and physical examinations. All AEs observed by the investigator and reported by the patients were recorded. They were categorized using the Medical Dictionary for Regulatory Activities coding dictionary.
Statistical analysis
Values are given as the mean ±s.d. A sample size of 160 evaluable patients (80 per group) would be required to detect a significant difference (defined as a 101 change in penile curvature) with 85% power for a type I error rate of a ¼ 0.05 between CoQ 10 and placebo (two sided). Assuming a 15% dropout rate, it was planned to randomize at least 184 patients. All analyses used an intention-to-treat principle, with inclusion of all randomized participants who completed at least one follow-up visit. The last observation carried forward was performed in the case of missing values for efficacy measures. Baseline and follow-up continuous parameters were compared using the two-tailed Student's t-test, whereas categorical variables were compared statistically using the w 2 -test. The paired t-test was used to compare the mean difference in pre-and posttreatment IIEF-5 scores. The Spearman's rank correlation coefficient, r s , was used to assess associations between study variables. A value of Po0.05 was considered statistically significant. Statistical Package for Social Sciences for Windows, version 17.0 (SPSS, Chicago, IL, USA), was used for statistical analysis.
Results
Patient disposition/demographics
Baseline demographic and clinical characteristics relative to the both groups are reported in Table 1 .
Differences in pretreatment characteristics between CoQ 10 and placebo groups were not statistically significant. In all, 81 (87.1%) patients in CoQ 10 group and 82 (88.2%) patients in placebo group completed the whole study period (Figure 1 ). The disease duration was 19.4±6.4 and 19.6±6.5 months in CoQ 10 and placebo groups, respectively.
Objective treatment results
Intergroup analysis revealed significant differences in terms of mean plaque size and mean penile curvature degree. In the CoQ 10 group, the overall improvement in penile curvature was 54.3% (n ¼ 44, Table 2 ). In 32 patients (39.5%), the deviation angle was decreased by more than 101. The mean curvature reduction was 121 (range: 4-201). The duration of the disease significantly affected the reduction of penile angulation (P ¼ 0.032). In 11 patients (13.6%), the penis was almost straight at 1-month follow-up period. In the placebo group, no significant difference regarding penile curvature was observed during the study period (P ¼ 0.001, Table 3 ). The objective improvements in penile curvature are shown in Figure 2 , which was documented by DPDU after intracavernosal injection of prostaglandin E 1 . Concerning plaque size, there were significant differences after treatment in CoQ 10 (Figure 3 , Table 3 ). Mean RI in both right and left penile artery increased by about 13% in CoQ 10 group, whereas a slight decrease was noted in the placebo group. Between-group differences were statistically significant (P ¼ 0.001). Mean PSV and EDV increased in both groups, but significant differences were found vs baseline values only in CoQ 10 group (P ¼ 0.01 and 0.001, respectively) ( Figure 3 , Table 3 ). Penile vascular status further deteriorated in the placebo group, and significant differences were found vs baseline values ( Figure 4 , Table 2 ). The IIEF-5 total score and placebo groups, the IIEF-5 total score increased by 117.1 and 8.6%, respectively (P ¼ 0.001) ( Figure 5 ). A significant difference in terms of SEP-2 and -3 questions was also reported in the CoQ 10 group when compared with baseline values, whereas no significant differences were found in the placebo group ( Figure 5 , Table 4 ). The EDITS data of patients are shown in Table 5 . At the end of trial, the corresponding mean EDITS index scores (maximum index score 100) were 68.6 ± 11.7 and 36.4 ± 10.6 for patients who took CoQ 10 and placebo, respectively (P ¼ 0.01). Overall, the proportion of patients satisfied with treatment, defined by Lewis et al.
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as a final EDITS score of 450, was 71.6% for the CoQ 10 and 12.2% for the placebo group (P ¼ 0.01). Similarly, mean intercourse per week was significantly higher when compared with baseline only in the CoQ 10 group (Table 4) . Intergroup analysis revealed significant differences in terms of patient perception of plaque volume and penile curvature. Mean plaque size and mean penile curvature degree decreased in the CoQ 10 group and increased in the placebo group (Table 4) . The number of patients answering yes to the GAQ question was 62.7% in CoQ 10 group and 12.4% in placebo group (P ¼ 0.001). At the end of trial, 24 (29.6%) of the 81 patients in CoQ 10 group reported that the results did not meet their expectations and requested another type of treatment.
Treatment results across different Kelami classifications
The response to the treatment significantly differed across different Kelami classifications (Table 2) .
Of the patients with class I, II and III deformity in CoQ 10 group, 4.6, 22.7 and 31.2% had deterioration of the curvature and 64.7, 45.5 and 31.2% had improvement, and the results obtained in this group were significantly better than those obtained in placebo group (all Po0.01). Of patients treated with CoQ 10 , the treatment resulted in improved sexual function in 65.1, 40.9 and 31.2% of patients with class I, II and III deformity, respectively; the respective values in the placebo group were 9.3, 9.1 and 6.2% (all P ¼ 0.001).
Penile artery spectral traces EDV and RI changed significantly at the end of study. Mean PSV changes after therapy compared with baseline were statistically significant between CoQ 10 (R (right), þ 13.3%, L (left), þ 13.8) and placebo-treated (R, þ 1.3, L, À6.5) patients (both P ¼ 0.001; Figure 3 ). There were also statistically significant differences in EDV and RI among the group (Table 3) . At the end of trial of patients in the CoQ 10 and placebo groups, 49 (53.8%) and 24 (26.1%) had nonvascular status, respectively (P ¼ 0.001, Figure 4) . When comparing differences in penile artery indices, patients with dorsolateral penile curvature had the highest rate of AI, at 39.1%. Patients with ventrolateral penile curvature had the best penile artery spectral traces, with a nonvascular status recorded in 73% of patients.
Safety and tolerability
Significant drug-related adverse effects did not occur in the two studied groups. No patient discontinued therapy because of side effects.
Disease progression
Of patients in the CoQ 10 group, 11 (13.7%) had disease progression, whereas 46 (56.1%) did so in the placebo group (P ¼ 0.01). Two patients (2.5%) in CoQ 10 group needed surgery, whereas 79 (97.5%) did not; in placebo group, 22 (26.8%) required surgery, whereas 60 (73.2%) did not (w 2 ¼ 4.619, P ¼ 0.001).
Secondary analysis
The distribution of baseline severity was similar, with similar numbers of mild (14, 15.1 vs 15, 16.1%), moderate (32, 34.4 vs 31, 33 .3%) and severe (47, 50.5 vs 47, 50.5%) ED in the CoQ 10 and placebo groups, respectively. Subgroup analyses did reveal trends in the CoQ 10 group to indicate that change in the IIEF-5 total score is affected by severity of ED. Improvement in the mean total score of IIEF-5 was higher in patients with moderate and severe ED. Subjects with moderate ED who received CoQ 10 showed the highest increase (138%) in the IIEF-5 total score at the end of the study compared with those who had mild (68%, P ¼ 0.001) and severe (94%, P ¼ 0.01) ED. Improvements were also significantly superior in the 40-50 years age group (72%) compared with the o40 and 450 years age groups (49 and 58%, respectively) over the total IIEF-5 score at the end of study (both Po0.01). There was a significant negative correlation between disease duration and a positive response to CoQ 10 (r ¼ À0.72, P ¼ 0.001), and between the Kelami class (r ¼ 0.74, P ¼ 0.001) and objective improvements and PSV (r ¼ 0.52, P ¼ 0.01). A positive response to CoQ 10 was significantly associated with treatment duration (r ¼ 0.76, P ¼ 0.001). There was a significant correlation between the degree of baseline ED and improvement in EF in response to CoQ 10 administration. Patients with moderate (r ¼ 0.68, P ¼ 0.001) and severe (r ¼ 0.52, P ¼ 0.01) ED had better positive response rates to CoQ 10 therapy than patients with mild ED.
Discussion
The results of this study have shown that CoQ 10 therapy produced improvements in plaque size, penile curvature, impaired sexual function and pain on erection. In addition to the complete improvement or significant reduction in penile plaque volume and the reduction in degree of penile curvature, subjective variable such as IIEF-5 total score and mean per-patient percent yes responses to GAQ improved after CoQ 10 supplementation (117 and 62.7%, respectively) in our participants. Furthermore, CoQ 10 administration prevented the progress of PD in 86% of patients and helped to stabilize the disease process. We could not find similar studies in literature for comparison. The chance of spontaneous resolution of PD (except of pain) is low. Current natural history studies on PD suggest spontaneous resolution rate of 5-13%. 5, 29 Our results underline the progressive nature of PD in placebo patients, characterized by a slow increase of both plaque size (35.7%) and penile curvature (28%). In this study, we also assessed the outcome of treatment objectively. A significant limitation of most previous studies is inaccuracy due to subjective assessments of outcome measures. 30 In a study by Mulhall et al., 29 the percentage of untreated patients complaining of some degree of ED was 32% with a mean IIEF-5 score of 19.2. Mean IIEF-5 scores we reported at baseline evaluation in both groups were much lower than to those reported by Mulhall et al. 29 However, similar to Mulhall et al., mean IIEF-5 total score did not change significantly in patients receiving no active treatment. This study reveals that, of the patients with PD, 19.9% were found to have pure AI by DPDU, whereas 25.3 and 29.6% revealed veno-occlusive dysfunction and mixed vascular disease, respectively. According to our results, it appears that the lowest improvement rate in sexual function were in men with pure AI. This would suggest that men with more advanced arterial-inflow disorders would be less likely to show an improvement in their ED. The role of oral medication to modify the course of PD may be limited to the 12-18 months of plaque maturation during which time penile pain and induration is gradually resolving. Once nonpainful penile curvature has been ensued, the probability of significant success with oral therapy appears limited.
PD negatively affects quality of life of both patients and partners, causing psychological distress. 31 The anxiety associated with the disease and the worrisome about intercourse because of pain and penile curvature are responsible for performance anxiety, thus contributing to impairment of EF. In our study of patients taking CoQ 10 and placebo, 51.9 and 8.5% reported subjective improvement in sexual function, respectively (P ¼ 0.001).
The postulated possible therapeutic mechanism of CoQ 10 on PD is that the reduced form of CoQ 10 (ubiquinone-10) is a potent lipophilic antioxidant. 32 In acute phase of PD, inflammation produces oxygen-free radicals. An inability to respond to this with antioxidants may cause the progress of the disease into chronic phase.
CoQ 10 is one of the most potent antioxidants, and may serve important roles in protection against ischemia and free radical oxygen injury. 15 Ohhara et al. 33 found that CoQ 10 protected against ischemia and reperfusion in the heart. CoQ 10 can interfere with the spontaneous progression of the disease through a stabilizing effect and shares the possible advantage of avoiding the need for surgery. Such an effect could be clinically relevant. Recent studies suggest that expression and activity of Smad transcription factors of the TGF-b pathway is increased in fibroblasts of patients with PD. Alterations in the TGF-b pathway appear to be a pathogenetic factor in the development of PD. 7 It has been demonstrated that TGF-b1 downregulates the expression levels and activity of antioxidant enzymes, including glutathione S-transferase, glutamate-cysteine ligase, superoxide dismutase and glutathione peroxidase. 34, 35 TGF-b1 inhibits antioxidant enzyme expression through Smad3/ATFdependent Nrf2 inactivation. 36 CoQ 10 decreases asmooth muscle actin and TGF-b1 expressions in Nrf2 wild-type mouse embryonic fibroblast cells. 16 Also, it has been reported that Nrf2 could initiate signal transduction pathways that regulate cell proliferation during development and in response to injury. 37 Several medical treatment options have been used in PD, with no confirmed benefit in clinical trials. 21, 25, 30, 38 However, various beneficial effects with some oral medications such as tamoxifen 39 and pentoxifylline 40 have also been reported. Despite many advances in identifying potential pathophysiological mechanisms, PD remains a therapeutic challenge, as no causal therapy is available until now. Our results confirm that CoQ 10 is safe and well tolerated. Most patients are satisfied and would like to continue the treatment.
Conclusions
In this study, significant differences were noted between baseline mean VAS score, mean IIEF-5 score and mean SEP-2 and -3 questions and posttreatment values in patients with early chronic PD receiving CoQ 10 . Also, significant differences in terms of mean plaque volume and preexisting mean penile curvature degree were evident in patients receiving CoQ 10 . The increasing of plaque size and worsening of penile curvature in the placebo group may suggest a potential protective effect of CoQ 10 on disease progression.
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